Non Alcoholic Fatty Liver Disease Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Non-Alcoholic Fatty Liver Disease Pipeline Insight 2023" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Non-Alcoholic Fatty Liver Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Non-Alcoholic Fatty Liver Disease Pipeline Insight Report

• DelveInsight's Non-Alcoholic Fatty Liver Disease pipeline analysis depicts a robust space with 80+ active players working to develop 100+ pipeline treatment therapies.

• The leading Non-Alcoholic Fatty Liver Disease Companies include BeiGene, Inventiva Pharma, Cirius Therapeutics, Inventiva Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmaceuticals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., Novartis, CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, and others.

• Promising Non-alcoholic Fatty Liver Disease Pipeline Therapies include Lanifibranor, Belapectin, ZED 1227, TVB-2640, ALS-L1023, MN-001, and others.

• The Non-alcoholic Fatty Liver Disease companies and academics are working to assess challenges and seek opportunities that could influence Non-Alcoholic Fatty Liver Disease R&D. The Non-alcoholic Fatty Liver Disease pipeline therapies under development are focused on novel approaches to treat/improve Non-Alcoholic Fatty Liver Disease.

Request a sample and discover the recent breakthroughs happening in the Non Alcoholic Fatty Liver Disease Pipeline landscapes @ Non Alcoholic Fatty Liver Disease Pipeline Outlook Report- https://www.delveinsight.com/report-store/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non Alcoholic Fatty Liver Disease Overview
Non-alcoholic fatty liver disease (NAFLD) is a broad term used to cover a spectrum of conditions that are characterized by evidence of hepatic steatosis on imaging or histology (macro-vesicular steatosis), and absence of secondary causes of hepatic steatosis such as significant alcohol consumption, chronic use of medications that can cause hepatic steatosis or hereditary disorders.

Recent Developmental Activities in the Non Alcoholic Fatty Liver Disease Treatment Landscape

• March 2024: Eli Lilly and Company announced a study of Phase 1 clinical trials for LY3849891. The main purpose of this study is to evaluate the safety and tolerability of the study drug LY3849891 in participants with nonalcoholic fatty liver disease who have the patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M genotype. Blood tests and magnetic resonance imaging of the liver will be performed to determine the effects of LY3849891 on fatty liver disease. Blood tests will also determine how long it takes the body to eliminate LY3849891. This is a 2-part study and may last up to 32 weeks for each participant and may include 12 and 13 visits in parts A and B, respectively.

• March 2024: GlaxoSmithKline announced a study of Phase 2 clinical trials for GSK4532990. The purpose of this study is to measure improvements in liver fibrosis and inflammation with GSK4532990 compared with placebo in participants with NASH and advanced fibrosis on biopsy (F3 or F4). The study duration will be up to 76 weeks including the screening period. The treatment duration will be up to 52 weeks.

For further information, refer to the detailed Non Alcoholic Fatty Liver Disease Drugs Launch, Non Alcoholic Fatty Liver Disease Developmental Activities, and Non Alcoholic Fatty Liver Disease News, click here for Non Alcoholic Fatty Liver Disease Ongoing Clinical Trial Analysis- https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Non Alcoholic Fatty Liver Disease Emerging Drugs Profile

Lanifibranor: Inventiva Pharma
Lanifibranor is an orally-available small molecule that acts to induce anti-fibrotic, anti-inflammatory, and beneficial metabolic changes in the body by activating each of the three PPAR isoforms, known as PPARα, PPARδ, and PPARɣ. Lanifibranor is a PPAR agonist that is designed to target all three PPAR isoforms in a moderately potent manner, with a well-balanced activation of PPARα and PPARɣ and partial activation of PPARɣ. It is currently in the Phase III stage of development and is being developed by Inventiva Pharma.

Belapectin: Galectin Therapeutics
Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins. Preclinical data in animals have shown that belapectin has robust treatment effects in reversing liver fibrosis and cirrhosis. It is currently in the Phase II/III stage of Clinical trial evaluation for Prevention of Esophageal Varices in NASH Cirrhosis.

ZED 1227: Dr. Falk Pharma GmbH
ZED 1227, is a synthetic peptidomimetic compound designed by Zedira scientists to specifically inhibit the enzymatic activity of human tissue transglutaminase (TG2). Dr. Falk Pharma has acquired the licensing rights to ZED1227 in Europe and several non-European countries and has assumed responsibility for pharmaceutical, preclinical, and clinical development of the new chemical entity towards a pharmaceutical product. By inhibiting TG2 in liver tissue, ZED1227 is expected to improve liver fibrosis in patients with NAFLD. It is currently in the phase II stage of development and is being developed by Dr. Falk Pharma GmbH.

TVB-2640: Sagimet Biosciences
TVB-2640 is an oral, selective, first-in-class fatty acid synthase inhibitor that directly targets the primary drivers of NASH by reducing excess liver fat (steatosis), decreasing inflammation and blunting fibrosis. In addition to the FASCINATE-2 trial, denifanstat is being tested in a Phase III clinical trial for recurrent glioblastoma and a Phase II study for moderate to severe acne. It is currently in the phase II stage of development and is being developed by Sagimet Biosciences.

ALS-L1023: AngioLab
ALS L1023 is a dried extract of ethyl acetate, prepared by activity-guided fractionation from Melissa leaf (lemon balm). The Angiogenesis Inhibitor ALS-L1023 from Lemon-Balm Leaves Attenuates High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Regulating the Visceral Adipose-Tissue Function. The drug is currently being investigated in Phase II clinical trials for the treatment of patients with Nonalcoholic Steatohepatitis.

MN-001: MediciNova
MN-001 (tipelukast) is a novel, orally bioavailable small molecule compound which exerts its effects through several mechanisms to produce its anti-fibrotic and anti-inflammatory activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. MN-001 has also known to reduce fibrosis in multiple animal models. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Nonalcoholic Steatohepatitis.

Non Alcoholic Fatty Liver Disease Pipeline Therapeutics Assessment
There are approx. 80+ key companies which are developing the therapies for Non-Alcoholic Fatty Liver Disease. The companies which have their Non-Alcoholic Fatty Liver Disease drug candidates in the most advanced stage, i.e. phase III include, Inventiva Pharma.

Find out more about the Non Alcoholic Fatty Liver Disease Pipeline Segmentation, Therapeutics Assessment, and Non Alcoholic Fatty Liver Disease Emerging Drugs @ Non Alcoholic Fatty Liver Disease Treatment Landscape- https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Non Alcoholic Fatty Liver Disease Pipeline Report

• Coverage- Global

• Non Alcoholic Fatty Liver Disease Companies- BeiGene, Inventiva Pharma, Cirius Therapeutics, Inventiva Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmacetuicals, Can Fite Biopharma, MediciNova, Metacrine, Inc., Lipocine, Inc., Novartis, CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno.N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, and others.

• Non Alcoholic Fatty Liver Disease Pipeline Therapies- Lanifibranor, Belapectin, ZED 1227, TVB-2640, ALS-L1023, MN-001, and others.

• Non Alcoholic Fatty Liver Disease Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Non Alcoholic Fatty Liver Disease Pipeline Companies and Therapies, click here @ Non Alcoholic Fatty Liver Disease Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Non-Alcoholic Fatty Liver Disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Non-Alcoholic Fatty Liver Disease - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Lanifibranor: Inventiva Pharma
9. Drug profiles in the detailed report…..
10. Last Stage Products (Phase II/III)
11. Belapectin: Galectin Therapeutics
12. Drug profiles in the detailed report…..
13. Mid Stage Products (Phase II)
14. ZED 1227: Dr. Falk Pharma GmbH
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. LB-P8: LISCure Biosciences
18. Drug profiles in the detailed report…..
19. Preclinical and Discovery Stage Products
20. Drug name: Company name
21. Drug profiles in the detailed report…..
22. Inactive Products
23. Non-Alcoholic Fatty Liver Disease Key Companies
24. Non-Alcoholic Fatty Liver Disease Key Products
25. Non-Alcoholic Fatty Liver Disease - Unmet Needs
26. Non-Alcoholic Fatty Liver Disease - Market Drivers and Barriers
27. Non-Alcoholic Fatty Liver Disease - Future Perspectives and Conclusion
28. Non-Alcoholic Fatty Liver Disease Analyst Views
29. Non-Alcoholic Fatty Liver Disease Key Companies
30. Appendix

Got Queries? Find out the related information on Non Alcoholic Fatty Liver Disease Mergers and acquisitions, Non Alcoholic Fatty Liver Disease Licensing Activities @ Non Alcoholic Fatty Liver Disease Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/non-alcoholic-fatty-liver-disease-nafld-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-
https://theventurecation.com/author/germanydennydones/
https://blogstudiio.com/fabry-disease-market-size/
https://meccapost.com/author/germanydennydones/
https://kitmaker.net/profile/yashveer-bhardwaj
http://www.costaricajobsearch.com/author/germanydennydones/
https://keralaclick.com/classified-advertising/user/profile/182882
https://aviator.forex.pm/?qa=user/germanydennydones
https://careers.coloradopublichealth.org/employers/2926283-delveinsight
https://www.heavyironjobs.com/profiles/4448319-denny-dones
https://jobs.blooloop.com/employers/2614577-delveinsight
https://www.animaljobsdirect.com/employers/2926436-delveinsight
https://jobs.windomnews.com/employers/2926467-delveinsight
https://jobs.fsoma.org/employers/2926471-delveinsight
https://jobs.thetab.com/employers/1458246-delveinsight
https://forum.squarespace.com/profile/421527-dennydonesgermany/?tab=field_core_pfield_1
https://camp-fire.jp/profile/germanydennydones
https://myaajkal.xyz/page/other/atopic-dermatitis-market-size/
https://talkotive.com/read-blog/136659
https://monstaluck.mn.co/posts/53508338
https://network-6063768.mn.co/posts/53508913
https://black-gun-association.mn.co/posts/53509422
https://charleston-wiffleball-association.mn.co/posts/53509543
https://network-6247558.mn.co/posts/53509666
https://franko-trading-enterprise.mn.co/posts/53509819
https://nordic-future.mn.co/posts/53509979
https://the-trifecta-network.mn.co/posts/53510053
https://diamond-members.mn.co/posts/53510731
https://tonow.mn.co/posts/53510860
https://network-1062788.mn.co/posts/53511032
https://d6united.mn.co/posts/53511102
https://mighty-networks-foundation.mn.co/posts/53511176
https://network-759413.mn.co/posts/53511779
https://walkinvirtualclinics.mn.co/posts/53511912
https://inbound-tourism-inner-circle.mn.co/posts/53512259
https://acertdglobalplatform.mn.co/posts/53512375
https://comidarealkitchen.mn.co/posts/53512492
https://ripple-xrp-global-network.mn.co/posts/understanding-the-atopic-dermatitis-market-size-forecast-and-outlook
https://facial546.mn.co/posts/53513294
https://moneyschoolinc.mn.co/posts/53513378
https://mylook-online.mn.co/posts/53513464
https://network-6063768.mn.co/posts/53513575
https://edpt200.mn.co/posts/53513922
https://decorated-with-members.mn.co/posts/53514022
https://fromfostercaretoceo.mn.co/posts/53514116
https://foodxtech.mn.co/posts/53514153
https://thinktrain.mn.co/posts/53514300
https://nc-cricket.mn.co/posts/53514349

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
https://www.delveinsight.com/report-store/radial-artery-compression-devices-market
https://www.delveinsight.com/report-store/uk-healthcare-outlook-report

This release was published on openPR.